Low rate of bacterial co-infection in patients with COVID-19

Hugh Adler; Robert Ball; Michael Fisher; Kalani Mortimer; Madhur S Vardhan

doi:10.1016/s2666-5247(20)30036-7

Low rate of bacterial co-infection in patients with COVID-19

Hugh Adler
, Robert Ball
, Michael Fisher
, Kalani Mortimer
, Madhur S Vardhan

Clinical Sciences

Liverpool School of Tropical Medicine

Research output: Contribution to journal › Letter › peer-review

54 Citations (Scopus)

Abstract

We agree with Michael J Cox and colleagues1 that clinical management of COVID-19 would be enhanced by further characterisation of bacterial co-infections. A few case reports have described examples of such co-infections.2, 3, 4 However, national5 and international6 guidelines recommend empirical antibiotics for all patients who are severely ill with suspected COVID-19, and that cessation of therapy is left to the clinicians' discretion. Pending the widespread availability of metagenomic sequencing as envisaged by Cox and colleagues,1 we argue that traditional diagnostics still have a role.

Original language	English
Pages (from-to)	E62
Journal	The Lancet Microbe
Volume	1
Issue number	2
DOIs	https://doi.org/10.1016/s2666-5247(20)30036-7
Publication status	Published - 1 Jun 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/s2666-5247(20)30036-7Licence: CC BY-NC-ND

HA LFinal published version, 40 KBLicence: CC BY-NC-ND

Cite this

@article{32f90ec9514847c3b236cdd89b381efc,

title = "Low rate of bacterial co-infection in patients with COVID-19",

abstract = "We agree with Michael J Cox and colleagues1 that clinical management of COVID-19 would be enhanced by further characterisation of bacterial co-infections. A few case reports have described examples of such co-infections.2, 3, 4 However, national5 and international6 guidelines recommend empirical antibiotics for all patients who are severely ill with suspected COVID-19, and that cessation of therapy is left to the clinicians' discretion. Pending the widespread availability of metagenomic sequencing as envisaged by Cox and colleagues,1 we argue that traditional diagnostics still have a role.",

author = "Hugh Adler and Robert Ball and Michael Fisher and Kalani Mortimer and Vardhan, \{Madhur S\}",

year = "2020",

month = jun,

day = "1",

doi = "10.1016/s2666-5247(20)30036-7",

language = "English",

volume = "1",

pages = "E62",

journal = "The Lancet Microbe",

issn = "2666-5247",

publisher = "Elsevier Ltd",

number = "2",

}

TY - JOUR

T1 - Low rate of bacterial co-infection in patients with COVID-19

AU - Adler, Hugh

AU - Ball, Robert

AU - Fisher, Michael

AU - Mortimer, Kalani

AU - Vardhan, Madhur S

PY - 2020/6/1

Y1 - 2020/6/1

N2 - We agree with Michael J Cox and colleagues1 that clinical management of COVID-19 would be enhanced by further characterisation of bacterial co-infections. A few case reports have described examples of such co-infections.2, 3, 4 However, national5 and international6 guidelines recommend empirical antibiotics for all patients who are severely ill with suspected COVID-19, and that cessation of therapy is left to the clinicians' discretion. Pending the widespread availability of metagenomic sequencing as envisaged by Cox and colleagues,1 we argue that traditional diagnostics still have a role.

AB - We agree with Michael J Cox and colleagues1 that clinical management of COVID-19 would be enhanced by further characterisation of bacterial co-infections. A few case reports have described examples of such co-infections.2, 3, 4 However, national5 and international6 guidelines recommend empirical antibiotics for all patients who are severely ill with suspected COVID-19, and that cessation of therapy is left to the clinicians' discretion. Pending the widespread availability of metagenomic sequencing as envisaged by Cox and colleagues,1 we argue that traditional diagnostics still have a role.

U2 - 10.1016/s2666-5247(20)30036-7

DO - 10.1016/s2666-5247(20)30036-7

M3 - Letter

SN - 2666-5247

VL - 1

SP - E62

JO - The Lancet Microbe

JF - The Lancet Microbe

IS - 2

ER -

Low rate of bacterial co-infection in patients with COVID-19

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this